Matches in SemOpenAlex for { <https://semopenalex.org/work/W37642080> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W37642080 endingPage "56" @default.
- W37642080 startingPage "46" @default.
- W37642080 abstract "This randomized, multicenter study compared the safety and efficacy of cefadroxil with that of cephalexin for the treatment of pyodermas in children and adolescents (1-18 years of age). Cefadroxil was given as a single oral daily dose of 30 mg/kg, and cephalexin 30 mg/kg/day was given in two divided doses. The maximum daily dose for both drugs was 1 gm, and treatment was administered for 10 days. Clinical and bacteriologic evaluations were made on days 4 or 5 during therapy and 2 to 4 days after therapy was completed. Of the 462 patients enrolled in the study, 156 patients in the cefadroxil group and 133 patients in the cephalexin group were evaluable. Staphylococcus aureus (56% of isolates) and Streptococcus pyogenes (39% of isolates) were isolated most frequently. The bacteriologic response was statistically greater in the patients treated with cefadroxil than in those treated with cephalexin (96% versus 89%; P = 0.042). A satisfactory clinical response was reported in 147 (94%) cefadroxil-treated patients and 122 (92%) cephalexin-treated patients (P = 0.476). The overall effective response to treatment was significantly higher with cefadroxil than with cephalexin (94% versus 86%; P = 0.024). Compliance with 9 or 10 days of therapy was similar in both treatment groups, although there was a difference between the two treatment groups with respect to completion of medication regimen: 95% of patients taking cefadroxil once daily--versus 65% of patients taking cephalexin twice daily--took 100% of their medication (P < 0.0001). Adverse events were infrequent and mild. The results of this study demonstrate that once-daily cefadroxil offers greater bacteriologic eradication and a better overall effective response than twice-daily cephalexin for the treatment of pyodermas caused by gram-positive pathogens in children and adolescents." @default.
- W37642080 created "2016-06-24" @default.
- W37642080 creator A5047836006 @default.
- W37642080 creator A5061255016 @default.
- W37642080 creator A5071592914 @default.
- W37642080 creator A5073852165 @default.
- W37642080 creator A5085154601 @default.
- W37642080 date "1993-01-01" @default.
- W37642080 modified "2023-09-26" @default.
- W37642080 title "Comparative evaluation of cefadroxil and cephalexin in children and adolescents with pyodermas. Cefadroxil Once Daily Pyoderma Study Group." @default.
- W37642080 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8458054" @default.
- W37642080 hasPublicationYear "1993" @default.
- W37642080 type Work @default.
- W37642080 sameAs 37642080 @default.
- W37642080 citedByCount "4" @default.
- W37642080 countsByYear W376420802015 @default.
- W37642080 crossrefType "journal-article" @default.
- W37642080 hasAuthorship W37642080A5047836006 @default.
- W37642080 hasAuthorship W37642080A5061255016 @default.
- W37642080 hasAuthorship W37642080A5071592914 @default.
- W37642080 hasAuthorship W37642080A5073852165 @default.
- W37642080 hasAuthorship W37642080A5085154601 @default.
- W37642080 hasConcept C126322002 @default.
- W37642080 hasConcept C16005928 @default.
- W37642080 hasConcept C168563851 @default.
- W37642080 hasConcept C197934379 @default.
- W37642080 hasConcept C2778961191 @default.
- W37642080 hasConcept C2780131815 @default.
- W37642080 hasConcept C2780947638 @default.
- W37642080 hasConcept C2781413609 @default.
- W37642080 hasConcept C501593827 @default.
- W37642080 hasConcept C64778159 @default.
- W37642080 hasConcept C71924100 @default.
- W37642080 hasConcept C86803240 @default.
- W37642080 hasConcept C89423630 @default.
- W37642080 hasConcept C90924648 @default.
- W37642080 hasConceptScore W37642080C126322002 @default.
- W37642080 hasConceptScore W37642080C16005928 @default.
- W37642080 hasConceptScore W37642080C168563851 @default.
- W37642080 hasConceptScore W37642080C197934379 @default.
- W37642080 hasConceptScore W37642080C2778961191 @default.
- W37642080 hasConceptScore W37642080C2780131815 @default.
- W37642080 hasConceptScore W37642080C2780947638 @default.
- W37642080 hasConceptScore W37642080C2781413609 @default.
- W37642080 hasConceptScore W37642080C501593827 @default.
- W37642080 hasConceptScore W37642080C64778159 @default.
- W37642080 hasConceptScore W37642080C71924100 @default.
- W37642080 hasConceptScore W37642080C86803240 @default.
- W37642080 hasConceptScore W37642080C89423630 @default.
- W37642080 hasConceptScore W37642080C90924648 @default.
- W37642080 hasIssue "1" @default.
- W37642080 hasLocation W376420801 @default.
- W37642080 hasOpenAccess W37642080 @default.
- W37642080 hasPrimaryLocation W376420801 @default.
- W37642080 hasRelatedWork W1534624784 @default.
- W37642080 hasRelatedWork W1982375125 @default.
- W37642080 hasRelatedWork W2108325310 @default.
- W37642080 hasRelatedWork W2419350565 @default.
- W37642080 hasRelatedWork W2780358035 @default.
- W37642080 hasRelatedWork W2808540294 @default.
- W37642080 hasRelatedWork W2968612804 @default.
- W37642080 hasRelatedWork W3111076045 @default.
- W37642080 hasRelatedWork W37642080 @default.
- W37642080 hasRelatedWork W64121902 @default.
- W37642080 hasVolume "15" @default.
- W37642080 isParatext "false" @default.
- W37642080 isRetracted "false" @default.
- W37642080 magId "37642080" @default.
- W37642080 workType "article" @default.